**Name of Journal:** *World Journal of Clinical Oncology*

**Manuscript No:** 53912

**Manuscript Type:** SYSTEMATIC REVIEWS

**Impact of primary tumour location on colorectal liver metastases: A systematic review**

Bingham G *et al*. Colorectal metastases, outcomes by primary location

George Bingham, Alysha Shetye, Reena Suresh, Reza Mirnezami

**George Bingham**, **Reena Suresh,** Department of General Surgery, St. Thomas’s Hospital, Lambeth, London SE1 7EH, United Kingdom

**Alysha Shetye, Reza Mirnezami**, Department of Colorectal Surgery, Royal Free Hospital, Hampstead, London NW3 2QG, United Kingdom

**Author contributions:** Bingham G and Shetye A have contributed equally. Bingham G, Shetye A, and Suresh R completed the initial literature review. Bingham G and Shetye A drafted the manuscript and tables. Mirnezami R developed the concept, led the editing process, and contributed to drafting the manuscript. All authors contributed to the critical revision, editing, and approval of the final version.

**Corresponding author: Reza Mirnezami, FRCS, MBBS, PhD, Surgeon, Consultant Colorectal Surgeon,** Department of Colorectal Surgery, Royal Free Hospital, Pond Street, Hampstead, London NW3 2QG, United Kingdom. reza.mirnezami@nhs.net

**Received:** December 31, 2019

**Revised:** May 9, 2020

**Accepted:** May 14, 2020

**Published online:** May 24, 2020

**Abstract**

BACKGROUND

Colorectal cancer (CRC) is the third most common cause of cancer-related death worldwide. Despite significant advances in screening, surgical management and adjuvant therapies, average 5-year survival seldom exceeds 60% in most developed nations. Metastatic disease represents the primary cause of mortality in patients with CRC, and the liver is the most common location for distant tumour spread. Up to 25% of patients are found to have synchronous liver metastases at the time of diagnosis and a further 30%-40% will develop metachronous disease in the course of follow-up. It has been suggested that primary tumour location [right side versus left side, Primary tumour location (PTL)] can influence oncological outcomes in this patient group and that this should be considered in prognostic models and therapeutic decision-making algorithms. This suggestion is not universally accepted and there have been conflicting reports in the literature to date.

AIM

To provide a comprehensive summary of the available evidence regarding the impact of PTL on oncological outcomes in patients with colorectal cancer liver metastases (CRCLM).

METHODS

MEDLINE, EMBASE and COCHRANE were searched for relevant publications using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses methodology. Data on oncological outcomes was then extracted from full text articles that met the predefined inclusion criteria.

RESULTS

A total of 41 studies were identified that met predefined inclusion criteria for this review. In 21 out of 38 studies that provided data on overall survival, a statistically significant improvement in overall survival was reported in patients with left sided primary tumours. These studies included a total of 13897 patients compared with 4306 patients in the studies that did not show a significant difference. Eight studies noted a similar trend towards improved disease-free or progression-free survival.

CONCLUSION

Interestingly, several authors have observed distinct patterns of relapse after treatment of hepatic metastases; for example, hepatic recurrence after treatment of CRCLM appears to occur more aggressively with right-sided CRC. Several mechanisms are likely to be responsible for these observed differences, and herein we outline molecular factors, histological and embryological differences and differences in therapeutic sensitivity according to PTL. Taken together, the findings of the present review indicate that PTL may have a role as an independent prognostic factor when determining treatment and disease surveillance strategies in CRC.

**Key words:** Liver metastasis; Colorectal cancer; Location; Primary tumour; Outcome

Bingham G, Shetye A, Suresh R, Mirnezami R. Impact of primary tumour location on colorectal liver metastases: A systematic review. *World J Clin Oncol* 2020; 11(5): 294-307

URL: https://www.wjgnet.com/2218-4333/full/v11/i5/294.htm

DOI: https://dx.doi.org/10.5306/wjco.v11.i5.294

**Core tip:** Primary tumour location is associated with differing oncological outcomes and patterns of hepatic metastatic behaviour in patients with colorectal cancer liver metastases. Specifically, this systematic review indicates that there is improved overall survival in patients undergoing treatment for colorectal cancer liver metastases with left-sided colorectal cancer (CRC), compared with right-sided CRC. These findings suggest that primary tumour location may have a role in developing more individually-tailored staging, treatment and surveillance strategies for patients with CRC in the future. Current chemotherapeutic regimens may require additional modification(s) to take into account the fundamental molecular and embryological differences that underpin primary tumour sidedness.

**INTRODUCTION**

Colorectal cancer (CRC) is the third most common cancer subtype world-wide with over 1 million new cases diagnosed in 2018[1]. Metastatic disease represents the primary cause of mortality in CRC, and up to 25% of patients are found to have synchronous metastases at the time of diagnosis. A further 40% will develop metachronous disease and approximately 25%-30% of patients will develop liver metastases in the course of follow-up[2]. Indications for curative intent treatment of CRC liver metastases (CRCLM) have expanded rapidly over the last three decades, and several key factors have led to improvements in outcome, notably enhanced radiological detection, improved chemotherapeutic efficacy and more aggressive surgical treatment[3]. With modern combined-modality treatment approaches, 5-year survival in excess of 50% has been reported in selected patients with CRCLM[4]. Clinico-pathological factors believed to be associated with worse oncological outcome in CRCLM include the presence of synchronous metastases, bi-lobar liver involvement, metastases > 5 cm in size, and the presence of extra-hepatic disease[4,5]. It has also been suggested by a number of authors that primary tumour location (PTL) - right side versus left side, can influence patterns of hepatic metastatic dissemination and survival[6,7]. For example, a number of studies have demonstrated inferior oncological outcome in patients undergoing surgical resection of CRCLM with right-sided versus left-sided colonic primary tumours[8-10]. This has not been a consistent observation, and others have shown no clear association[11,12]. The aim of the present systematic review is to provide a summary of the available evidence on the impact of PTL on oncological outcomes in patients with CRCLM.

**MATERIALS AND METHODS**

***Identification of studies***

An electronic literature search was carried out using MEDLINE (1965 to March 2020), EMBASE (1980 to March 2020) and the Cochrane Library databases. The medical subject heading terms and key words used are as follows: “Colon” or “rectal cancer”, “liver metastasis” or “liver metastases” or “hepatic metastasis” or “hepatic metastases” and “left” and “Right”. Studies, abstracts and citations were scanned for relevance. The latest date of this search was 27 March 2020. The publications deemed relevant were read in full and assessed for inclusion and their references scanned to identify papers not identified in the initial search.

***Inclusion criteria***

The methodology was designed around the “Preferred Reporting Items for Systematic Reviews and Meta-Analyses” recommendations for improving the standard of systematic reviews[13].

**Studies meeting the following criteria were included for review:** (1) Language:Full article accessible in English language only; Conference abstracts only were excluded. (2) Patient population: Studies reporting outcomes in ≥ 10 male/female patients aged ≥ 18 years with colorectal cancer and liver metastases. Where multiple publications were identified covering overlapping periods of time from the same institution/research group, the most recent and/or relevant data were selected for inclusion, and (3) Outcome measures: Studies were included if they reported oncological outcome data such as overall survival (OS), progression-free survival (PFS), recurrence-free survival (RFS) or disease-free survival (DFS). Studies reporting oncological outcomes for metastatic colorectal cancer were excluded if results were not reported for liver metastases specifically. Patients with metastases at multiple sites were included if one site was liver.

***Data extraction***

Three authors (Bingham G, Shetye A, Suresh R) independently extracted the following data from eligible studies: First author, year of publication, country of origin, study type, number of patients by gender, site of primary and age, primary study endpoint(s), secondary endpoint(s), extent and distribution of liver metastases, follow-up duration, adjuvant/neoadjuvant management, overall survival, progression-free survival, recurrence-free survival. Where there was uncertainty regarding inclusion a second author was consulted for consensus. All papers included were graded according to level of evidence using the system proposed by the Scottish Intercollegiate Guidelines Network[14]. A Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow-diagram summarising the above search strategy is provided in Figure 1.

**RESULTS**

A total of 4094 potentially relevant publications were initially identified through the search strategy summarised in Figure 1. After screening of titles and abstracts, 3700 publications were withdrawn, leaving 394 articles for full text review. A reference search from these articles identified a further 26 studies of potential relevance. Of the 420 full text publications that were evaluated, 41 studies, including a total of 18426 patients, were found to meet our predefined inclusion criteria and were included in the review process. Study characteristics from these 41 studies are summarised in Table 1. Study population in these studies ranged from 24 to 3125 patients. Studies comprised two cohort prospective studies[15,16] (evidence level 2+) and 39 retrospective studies (evidence level 2+ - 2++)[8-12,17-50], this included 6 papers with pooled analysis (evidence level 2+-2++)[10,12,15,16,18,49]. There were no randomised controlled trials.

***Overall survival***

Data on the influence of PTL on OS in CRCLM was provided by 38 of the studies included for review, including a total of 18203 patients. In 21 of these studies (13897 patients -76.3% of the total patient population captured) a statistically significant trend was observed with improved OS in patients with left sided primary tumours undergoing treatment for CRCLM (*l*-CRCLM). For example, Wang *et al*[17] in their study of 1508 patients receiving surgical treatment for synchronous CRCLM, of which 593 had right sided primary colorectal tumours (*r*-CRCLM), found a significant difference in 5-year OS between left and right sided primaries (*l*-CRCLM 40.1%, *r*-CRCLM 24.6%, *P <* 0.001). They also found that patients with *r*-CRCLM were more likely to be T4 (31.3% *vs* 20.1%, *P <* 0.001) N2 (42.5% *vs* 31.8%, *P* < 0.001), and poorly differentiated (30.5% *vs* 15.1%, *P <* 0.001). Creasy *et al*[9] in a similar cohort of 907 patients (36% with right sided primaries) undergoing hepatic resection found a found a median OS of 5.2 years in *l*-CRCLM compared with 3.6 years with in *r*-CRCLM (*P =* 0.004), with a hazard ratio (HR) of 1.22 (*P =* 0.028) on multivariate analysis. In their population database study of 3125 patients in Sweden Norén *et al*[18] found that *l*-CRCLM extended median OS by 4 mo (*P =* 0.02) compared with *r*-CRCLM. In addition, the authors reported enhanced 5-year OS (45.8% *vs* 44.5% *P =* 0.02), with a HR of 0.75 for *l*-CRCLM (*P <* 0.001).

A further 17 studies with 4306 patients found no statistically significant difference in OS between the two groups, but there was a trend towards longer OS in patients with *l*-CRCLM on the whole. For example, Gasser *et al*[12] found patients with a *l*-CRCLM had 22 mo longer median overall survival compared to *r*-CRCLM (*P =* 0.051). This contrasts with only 2 studies that showed lower OS in patients with *l*-CRCLM study, Dulundu *et al*[19] and Viganò *et al*[20], but neither with statistical significance (*P =* 0.072 and *P >* 0.05 respectively). These results are summarised in Table 2.

***Disease-free survival***

Benefit in DFS was also suggested, but not as convincingly as OS. This data was more sparsely provided, as some authors opted to alternatively provide PFS. Four studies including 3013 patients showed improved DFS in *l*-CRCLM. Russolillo *et al*[21] found improved median DFS by almost 1 year (32.7 mo *vs* 20.8 mo, *P =* 0.002) in their 364 patients with *l*-CRCLM (*vs* 322 patients with *r*-CRCLM) when assessing patterns of recurrence and survival following resection of liver metastases. In 2017 Heise *et al*[22] reported a DFS benefit in patients with *l*-CRCLM undergoing repeat hepatectomy after recurrence of colorectal cancer (HR: 0.19, *P =* 0.001). Liao *et al*[10] studied 1442 patients with stage III CRC who went on to develop CRCLM, and found that patients with left-sided colon cancer had better 3-year DFS (70.9% *vs* 66.5%, *P =* 0.033) compared to those with *r*-CRCLM.

In contrast to these observations, only one study by Sasaki *et al*[23] found significantly improved 3-year DFS in patients with *r*-CRCLM (28% *vs* 20.2%, *P =* 0.001) in their study of 426 patients who were undergoing curative intent hepatectomy.

Thirteen studies with 3423 patients showed no significant difference in DFS between *l*-CRCLM and *r*-CRCLM. These results are summarised in Table 3.

***Progression-free survival***

Only five publications provided data on PFS, and these data are summarised in Table 4. These studies including 2805 patients showed significantly improved PFS in *l*-CRCLM versus *r*-CRCLM. For example, de Haas *et al*[24] showed in 726 patients undergoing hepatic resection for CRCLM, that patients with *l-*CRCLM had a higher 5-year PFS (18% *vs* 16%, *P =* 0.009). No papers give significant evidence to the contrary and only one study with 63 patients showing no significant difference[25].

**DISCUSSION**

The data summarised in this systematic review appear to support the suggestion that CRCLM arising from right-sided colorectal primary tumours are associated with inferior OS compared with those arising from the left-sided CRC. Specifically, 21 of the 38 studies that provided data on OS reported statistically significant inferior OS in patients with *r*-CRCLM. Liao *et al*[10] for example demonstrated in their large study of 1442 patients that patients with *l-*CRCLM had better 5-year OS, 5-year cancer-specific survival, and 5-year RFS, all with statistical significance. In 2018 Yamashita *et al*[26] similarly concluded in their cohort of 725 patients undergoing upfront hepatic resection, that there was a significant survival benefit to having *l-*CRCLM, but that this benefit was no longer evident after neoadjuvant chemotherapy. The relationship between primary site and DFS and PFS with CRCLM is less clear, though again there appears to be a trend towards improved oncological outcome in *l*-CRCLM. Explaining these variations in oncological outcome is likely to require a deeper understanding of the underlying molecular and embryological differences associated with primary tumour sidedness.

There are subtleties in regards to variable oncological outcome identified in this review that merit further discussion. For example, in terms of DFS, Sasaki *et al*[23] reported interesting findings in terms of patterns of relapse with *l*-CRCLM compared with *r*-CRCLM. Specifically, in their study patients with *l*-CRCLM exhibited a shorter disease-free interval compared with patients who had undergone treatment for *r*-CRCLM (*P =* 0.01). However, irrespective of timing of relapse, and in spite of a longer disease-free interval, when patients with *r*-CRCLM did succumb to hepatic recurrence, it was consistently found to be with more advanced disease (> 4 recurrent lesions, *P <* 0.01). As a result, the authors found significantly reduced OS and significantly reduced survival after recurrence in *r*-CRCLM, compared with *l*-CRCLM. Thus it is conceivable, for reasons as yet unclear, that the liver is able to “hold off” recurrence of hepatic metastases arising from right-sided primaries for longer, but also that when this does finally occur, it is a more aggressive pattern of progression, leading to the paradoxical observation in some studies of seemingly favourable disease free interval, but ultimately inferior OS with *r*-CRCLM.

Previously the suggestion has been made that the typically more indolent course of presentation of right CRC, might in part be responsible for inferior outcome with resulting liver metastases[10]. The notion here is that delayed diagnosis of primary tumour results in an increased risk of developing synchronous metastases which are then incurable[51]. This would mean potentially fewer curative-intent resections offered to these patients, resulting in observed abbreviated survival. However, in this study we have also shown that there is evidence that PTL also has prognostic impact in patients with unresectable disease from the outset. For example, Zhou *et al*[27] reported on outcomes in 295 patients with unresectable CRCLM undergoing palliative radio-frequency ablation, and found similar rates of OS, but that the PFS was significantly better in patients with *l*-CRCLM (HR: 0.67, *P =* 0.012). Gu *et al*[28] also reported outcomes following palliative-intent radio-frequency ablation in patients with CRCLM, finding that patients with *l*-CRCLM had a significantly lower risk of recurrence outside of the ablation zone, with increased OS of 40.3 mo compared with 29.4 mo in *r*-CRCLM(*P =* 0.042). Multivariate analysis confirmed a HR of 6.2 (*P =* 0.001) for *r*-CRCLM predicting OS. This data is further supported by findings reported by Chafai *et al*[29] in 2005, who studied patients with unresected synchronous liver metastases after resection of the primary tumour. They found a significantly shorter survival in palliative patients who had *r*-CRCLM compared with *l*-CRCLM (2 years survival 9.9% *vs* 22.2%, HR: 1.5 *P <* 0.001). In circumstances where palliative/debulking surgery is offered, differences continue to persist for l-CRCLM versus r-CRCLM. For example, in 2017 Zhang *et al*[30] found that hepatic palliative resection prolonged median OS by 8 mo in patients with *l*-CRCLM (palliative resection *vs* no resection: 22 mo *vs* 14 mo, *P =* 0.009); however, by comparison no such improvement in OS was observed for patients with *r*-CRCLM undergoing palliative resection (12 mo *vs* 10 mo, *P =* 0.910).

With regards to defining putative mechanistic explanations for these differences, a number of factors should be considered. Firstly, there is considerable evidence that right sided CRCs are significantly more likely to harbor negative prognostic features; they tend to present at a more advanced stage, often in older patients, with a greater chance of synchronous metastatic disease, are more likely to carry unfavourable genetic mutation(s), and show poor differentiation[18,21,27,31,52]. It could therefore follow that patients with right sided CRC simply present with more advanced and aggressive disease from the outset. This however was not a uniform finding across the studies included in this review. For example, Creasy *et al*[9] found no such differences between right sided versus left sided CRC in terms of proportion of patients with the largest metastasis > 5 cm, proportion of patients with multiple metastases, or the proportion of patients with extra-hepatic disease. In spite of this relative equipoise, the authors reported significantly improved OS in patients with *l-*CRCLM and suggest that unique differences based on sidedness are likely to exist that extend beyond the aforementioned conventionally accepted differences.

From this perspective a number of mechanisms have emerged that could play a role in contributing to the inferior oncological outcome observed in patients with *r*-CRCLM. These broadly can be considered as: (1) Molecular differences; (2) Histopathological differences; (3) Therapeutic sensitivity differences; and (4) Embryological differences.

***Molecular differences***

There are well-established molecular differences between right- and left-sided CRC with the former more often exhibiting *KRAS* and/or *BRAF* mutation[12,33,34,53]. RAS mutations have consistently been found to be associated with more aggressive tumour biology and are identified in up to 45% of patients with metastatic CRC. For example, the studies published by Amikura *et al*[32] and Shindoh *et al*[54] both demonstrate that RAS mutational status is associated with significantly worse survival in CRCLM (Amikura *et al*[32]: 5-year OS: 42.4% *vs* 65.3%, *P =* 0.0006; Shindoh *et al*[54]: 3-year DFS 59.9 *vs* 83.6% *P =* 0.016). Of note, it has also been reported that among patients put forward for curative intent resection of CRCLMs, the incidence of RAS mutation is only around 10%-15%, indicating that underlying tumour biology, seemingly inseparably linked to PTL, exerts additional prognostic relevance as it appears to indirectly influence surgical candidacy[55]. Goffredo *et al*[56] evaluated outcomes in 2655 patients undergoing CRCLM resection. They observed a significant increase in likelihood of mutant KRAS with right-sided PTL, compared to left and correspondingly found reduced OS in patients with *r*-CRCLM. It is likely that additional molecular drivers are responsible for the variations seen according to PTL, and RAS/BRAF likely account for only part of the molecular landscape especially since only a limited proportion of these cases are put forward for resection[54]. This notion is supported by Huang *et al*[57] who found no significant association between KRAS/BRAF mutational status and prognosis in patients presenting with metachronous CRCLM.

The role of mismatch repair (MMR) status and microsatellite instability (MSI) in the context of PTL seems less certain. Right sided CRC is more frequently associated with deficient MMR and MSI[7,56,58]. These tumours tend to be typified by poor differentiation, mucinous features and lymphocytic invasion. Evidence supports the suggestion that MSI is associated with improved oncological outcome[59,60]. However, this is at odds with the findings of the present review, where *r*-CRCLM appears to have shortened survival. This may reflect fundamental differences in MMR status according to tumour stage. For example, Jernvall *et al*[61] found MSI to be a more common finding in right sided Stage II CRC, but this was less frequently observed in stage IV disease. In this review molecular data were only available from a limited number of publications and subdivision of molecular phenotype according to PTL has not been provided in most cases. Hence, we are not able to draw any more definitive conclusions on the precise interplay between molecular factors and PTL. Considering these limitations, The Cancer Genome Atlas Network sought to evaluate a broader panel of genetic mutations and defined cases as ‘hypermutated’ where a mutation rate of > 12/106 bases was found. Out of 276 samples analysed, the majority of hypermutated cases were right sided primary tumours. The group suggest that hypermutated phenotype is a significant negative prognostic feature, and this may in part account for inferior survival with *r*-CRCLM, as noted in the present review[62].

***Histological differences***

Several investigators have evaluated tumour histopathological features in order to determine if the difference in sidedness outcomes and tumour aggressiveness can be explained by one or more of these. Desmoplastic growth behaviour, presence of poorly differentiated clusters and tumour budding have all been considered[25,41,63]. Strong evidence, however, relates to the prevalence of mucinous elements. Viganò *et al*[20] and Russolillo *et al*[21] have both demonstrated mucinous adenocarcinoma to be more prevalent in right-sided CRC (*P =* 0.002 and *P =* 0.001, respectively). Viganò *et al*[20] reported significantly shortened OS with *r*-CRCLM versus *l*-CRCLM. They observed that, when compared with non-mucinous carcinoma, mucinous carcinoma has a higher KRAS mutation rate 61.8% *vs* 36.4%; *P =* 0.037) and lower chemotherapy response rate (63.9% *vs* 85.2%; *P =* 0.006). Specifically, Viganò *et al*[20] reported lower 5-year OS (33.2% *vs* 55.2%; *P =* 0.010) and DFS (32.5% *vs* 49.3%; *P =* 0.037) for mucinous tumours undergoing hepatic resection. One can extrapolate from these observations that inferior survival and right sided PTL are linked by an increased tendency for mucinous histology.

***Therapeutic sensitivity differences***

There are also suggestions in the literature that chemosensitivity is important in predicting survival, and that there may be a differing chemosensitivity profile according to PTL. In their meta-analysis of 16 first-line trials evaluating the efficacy of chemotherapy alone *vs* chemotherapy with targeted biologics in patients with unresectable metastatic CRC, You *et al*[64] found survival of patients with right sided CRC was inferior to those with left in patients receiving chemotherapy alone, implying that right-sided tumours overall are less chemosensitive. This finding is supported by Yamashita *et al*[26] found that *r*-CRCLM were independently associated with “minor pathological response” (defined as cancer cells accounting for ≥ 50% of residual cells), and were thus less sensitive to chemotherapy with worse RFS and OS. Interestingly, Marques *et al*[11] found that when selecting patients for CRCLM resection based on chemosensitivity, the survival disadvantage seen with *r*-CRCLM was eliminated. This suggests fundamental differences in tumour biology with the less chemosensitive phenotype more frequently seen with right-sided PTL and in turn associated with poorer survival.

This difference is maintained after the addition of well-established antiangiogenic biologics. You *et al*[64] found inferior survival in patients with *r*-CRCLM receiving chemotherapy and bevacizumab compared with *l*-CRCLM. Zheng *et al*[31] studied the effect of cetuximab as an addition to chemotherapy in KRAS wild-type patients with initially unresectable hepatic metastases. They found a survival benefit to cetuximab in patients with both *r*-CRCLM and *l*-CRCLM, but importantly noted that this effect was more substantial in the latter, with higher rates of effective tumour downstaging and extended OS.

***Embryological differences***

In terms of embryology, Yamashita *et al*[26] suggest that the mid-gut embryological origin of the right colon may be responsible for the variable responsiveness of *r*-CRCLM to chemotherapy and differing oncological outcomes. Specifically, in their study of outcomes in 725 patients, they found reduced responsiveness to chemotherapy, reduced RFS and reduced OS in patients with *r*-CRCLM. The authors reported that this difference was maintained irrespective of RAS mutational status, which is considered to be one of the key oncogenic differences between right- and left-sided colon cancers. It is possible however, that other factors centered around the distinct development of these regions of gut, including unique lymphatic and venous drainage basins, and exposures to unique types of bacterial flora, could be contributing to oncological variability. This is an area that requires further research.

***Limitations***

As a systematic review this paper has some inherent limitations, it is restricted by the quality of the literature available. However, all included papers were graded using the SIGN criteria with small studies excluded to mitigate this. Care was taken to perform a complete literature search, but studies and some work in progress may have been missed. Larger studies and well as future meta-analysis will be necessary to more clearly establish this trend and may provide a deeper understanding of the mechanisms at play.

In conclusion, the present review provides compelling data to support the notion that PTL significantly influences oncological outcome in patients with CRCLM. Overall, the data presented indicate that patients with *r*-CRCLM appear to have truncated overall, disease-free and progression-free survival. Some of these differences are likely to be accounted for by molecular heterogeneity, but other factors such as embryological origin and colonic microbiotal composition are areas that have received comparatively less attention in terms of research, and these may represent promising avenues to explore in the future. With the understanding that PTL could have prognostic relevance, comes the need to adjust treatment pipelines for patients accordingly. For example, patients with right-sided CRC may require abbreviated intervals between surveillance scans and tumour-marker assessment after primary tumour resection. In addition, given their more aggressive pattern of recurrence after hepatic resection/treatment, patients with *r*-CRCLM may benefit from a more radical first-line treatment of hepatic metastases. For example, the role of non-anatomical resection and the use of locally-ablative techniques in *r*-CRCLM may need more careful consideration.

**ARTICLE HIGHLIGHTS**

***Research background***

Colorectal cancer (CRC) is the third most common cause of cancer related death with liver being the most common metastatic site. It has been long suggested that left and right sided primary tumours exhibit different behaviour but relatively little has been written about how this relates specifically to outcomes in colorectal cancer with liver metastases (CRCLM).

***Research motivation***

We hope to increase understanding regarding the impact of sidedness in colorectal cancer with liver metastases given the relative paucity of information in this specific are. Given the prevalence of CRC, improving understanding of its various presentations in order guide further research as well as clinical practice can have a huge impact on patient morbidity and mortality.

***Research objectives***

We aim to ascertain if there is a significant difference in oncological outcomes in patients with colorectal cancer and liver metastases depending on their primary tumour location and to present some hypotheses that may explain any differences found. These objectives were realised with this review demonstrating a significant difference in outcomes based on primary tumour location (PTL). Further work is needed to better characterise these mechanisms so that this knowledge can be used to inform clinical decision making.

***Research methods***

A systematic review of Medline, Cochrane and Embase using the Terms “The medical subject heading terms and key words used are as follows: “Colon” or “rectal cancer”, “liver metastasis” or “liver metastases” or “hepatic metastasis” or “hepatic metastases” and “left” and “Right”. This search was combined with a bibliographic search to find the relevant publications and extract data from these papers. The methodology was based around the Preferred Reporting Items for Systematic Reviews and Meta-Analyses’ recommendations for systematic reviews

***Research results***

Twenty-one studies with a total of 18203 patients showed a statistically significant trend of improved overall survival in patient with left sided primary tumours undergoing treatment for colorectal cancer liver metastases (*l*-CRCLM). Four studies including 3013 patients showed improved disease free survival (DFS) in *l*-CRCLM. Only five publications provided data on progression free survival (PFS). These studies including 2805 patients showed significantly improved PFS in *l*-CRCLM *vs* *r*-CRCLM. The findings of this review are congruent with the accepted premise of superior survival in left sided colorectal cancer, and uniquely show that this remains true in the context of metastatic liver disease. We highlight a number of factors that may contribute to this, including KRAS/BRAF mutational status, presence of mucinous elements, and impaired chemosensitivy –all which are shown to be associated with right-sided PTL. The exact interplay between these known factors, PTL, and the emerging new mutations and molecular markers is yet to be determined and work needs to be done to determine the importance of PTL within the conglomeration.

***Research conclusions***

The findings of this review indicate that PTL may have a role as an independent prognostic factor when determining treatment and disease surveillance strategies specifically in colorectal cancer that has metastasised to the liver. We find improved survival for both resected and unresectable *l-*CRCLM as well as a maintained trend after addition of biologics to established chemotherapy regimens. Hepatic recurrence after treatment of CRCLM appears to occur more aggressively with right-sided CRC, conferring significantly reduced survival. Explaining these variations in oncological outcome requires a deeper understanding of the underlying molecular and embryological differences associated with primary tumour sidedness. Microsatellite instability, interestingly, whilst more common in right-sided tumours, has been shown to be independently associated with improved survival – a finding somewhat incongruent with the overall picture of inferior survival in *r-*CRCLM. This suggests alternative mechanisms beyond MMR and microsatellite instability are likely to be involved. KRAS and BRAF mutational status, mucinous adenocarcinoma, and impaired chemosensitivity are all known to be significantly associated with right-sided CRC, and we show here that this association and the accompanying inferior survival persists in *r*-CRCLM. A better understanding of the role of PTL in the oncological outcomes of metastatic CRC may allow for improved risk stratification and redesigned patient pathways.

***Research perspectives***

There is a considerable amount of data available on the oncological outcomes of patients undergoing liver resection for CRCLM, as related to PTL. This shows with convincing evidence that outcomes are superior for patients with *l-*CRCLM. Future research should be focused on gathering associated molecular and genetic data as related to PTL to better understand the tumour biology of right-sided CRC. This may allow the determination of ideal molecular markers, both for risk stratification / prognostication, and that may be used as potential therapeutic targets.

**REFERENCES**

1 **Bray F**, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2018; **68**: 394-424 [PMID: 30207593 DOI: 10.3322/caac.21492]

2 **Vatandoust S**, Price TJ, Karapetis CS. Colorectal cancer: Metastases to a single organ. *World J Gastroenterol* 2015; **21**: 11767-11776 [PMID: 26557001 DOI: 10.3748/wjg.v21.i41.11767]

3 **Tejpar S**, Stintzing S, Ciardiello F, Tabernero J, Van Cutsem E, Beier F, Esser R, Lenz HJ, Heinemann V. Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials. *JAMA Oncol* 2017; **3**: 194-201 [PMID: 27722750 DOI: 10.1001/jamaoncol.2016.3797]

4 **House MG**, Ito H, Gönen M, Fong Y, Allen PJ, DeMatteo RP, Brennan MF, Blumgart LH, Jarnagin WR, D'Angelica MI. Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution. *J Am Coll Surg* 2010; **210**: 744-752, 752-755 [PMID: 20421043 DOI: 10.1016/j.jamcollsurg.2009.12.040]

5 **Arru M**, Aldrighetti L, Castoldi R, Di Palo S, Orsenigo E, Stella M, Pulitanò C, Gavazzi F, Ferla G, Di Carlo V, Staudacher C. Analysis of prognostic factors influencing long-term survival after hepatic resection for metastatic colorectal cancer. *World J Surg* 2008; **32**: 93-103 [PMID: 18027020 DOI: 10.1007/s00268-007-9285-y]

6 **Jess P**, Hansen IO, Gamborg M, Jess T; Danish Colorectal Cancer Group. A nationwide Danish cohort study challenging the categorisation into right-sided and left-sided colon cancer. *BMJ Open* 2013; **3**: e002608 [PMID: 23793665 DOI: 10.1136/bmjopen-2013-002608]

7 **Nitsche U**, Stögbauer F, Späth C, Haller B, Wilhelm D, Friess H, Bader FG. Right Sided Colon Cancer as a Distinct Histopathological Subtype with Reduced Prognosis. *Dig Surg* 2016; **33**: 157-163 [PMID: 26824772 DOI: 10.1159/000443644]

8 **Dupré A**, Malik HZ, Jones RP, Diaz-Nieto R, Fenwick SW, Poston GJ. Influence of the primary tumour location in patients undergoing surgery for colorectal liver metastases. *Eur J Surg Oncol* 2018; **44**: 80-86 [PMID: 29183640 DOI: 10.1016/j.ejso.2017.10.218]

9 **Creasy JM**, Sadot E, Koerkamp BG, Chou JF, Gonen M, Kemeny NE, Saltz LB, Balachandran VP, Peter Kingham T, DeMatteo RP, Allen PJ, Jarnagin WR, D'Angelica MI. The Impact of Primary Tumor Location on Long-Term Survival in Patients Undergoing Hepatic Resection for Metastatic Colon Cancer. *Ann Surg Oncol* 2018; **25**: 431-438 [PMID: 29181680 DOI: 10.1245/s10434-017-6264-x]

10 **Liao CK**, Chiang JM, Tsai WS, You JF, Hsieh PS, Hung HY, Chen HH, Tang RP, Chen JS, Yeh CY. Primary tumor location in stage III colon cancer has prognostic impact on subsequent liver metastasis. *J Surg Oncol* 2018; **118**: 1301-1310 [PMID: 30408183 DOI: 10.1002/jso.25270]

11 **Marques MC**, C Ribeiro HS, Costa WL Jr, de Jesus VHF, de Macedo MP, Diniz AL, Godoy AL, Farias IC, Aguiar S Jr, Riechelmann RSP, S Begnami MDF, Coimbra FJF. Is primary sidedness a prognostic factor in patients with resected colon cancer liver metastases (CLM)? *J Surg Oncol* 2018; **117**: 858-863 [PMID: 29611198 DOI: 10.1002/jso.25048]

12 **Gasser E**, Braunwarth E, Riedmann M, Cardini B, Fadinger N, Presl J, Klieser E, Ellmerer P, Dupré A, Imai K, Malik H, Baba H, Ulmer H, Schneeberger S, Öfner D, Dinnewitzer A, Stättner S, Primavesi F. Primary tumour location affects survival after resection of colorectal liver metastases: A two-institutional cohort study with international validation, systematic meta-analysis and a clinical risk score. *PLoS One* 2019; **14**: e0217411 [PMID: 31150437 DOI: 10.1371/journal.pone.0217411]

13 **Moher D**, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med* 2009; **6**: e1000097 [PMID: 19621072 DOI: 10.1371/journal.pmed.1000097]

14 **Harbour R,** Miller J. A new system for grading recommendations in evidence based guidelines. *Br J Med* 2001; **323**: 334–336 [PMID: 1149849 DOI: 10.1136/bmj.323.7308.334]

15 **Rougier P**, Milan C, Lazorthes F, Fourtanier G, Partensky C, Baumel H, Faivre J. Prospective study of prognostic factors in patients with unresected hepatic metastases from colorectal cancer. Fondation Française de Cancérologie Digestive. *Br J Surg* 1995; **82**: 1397-1400 [PMID: 7489177 DOI: 10.1002/bjs.1800821034]

16 **Cremolini C**, Milione M, Marmorino F, Morano F, Zucchelli G, Mennitto A, Prisciandaro M, Lonardi S, Pellegrinelli A, Rossini D, Bergamo F, Aprile G, Urbani L, Morelli L, Schirripa M, Cardellino GG, Fassan M, Fontanini G, de Braud F, Mazzaferro V, Falcone A, Pietrantonio F. Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials. *Br J Cancer* 2018; **118**: 955-965 [PMID: 29531324 DOI: 10.1038/s41416-018-0015-z]

17 **Wang Z**, Wang X, Zhang Z, Wang X, Chen M, Lu L, Zhu W, Zhang J, Jia H, Chen J. Association between Primary Tumor Location and Prognostic Survival in Synchronous Colorectal Liver Metastases after Surgical Treatment: A Retrospective Analysis of SEER Data. *J Cancer* 2019; **10**: 1593-1600 [PMID: 31205514 DOI: 10.7150/jca.29294]

18 **Norén A**, Eriksson HG, Olsson LI. Selection for surgery and survival of synchronous colorectal liver metastases; a nationwide study. *Eur J Cancer* 2016; **53**: 105-114 [PMID: 26702764 DOI: 10.1016/j.ejca.2015.10.055]

19 **Dulundu E**, Attaallah W, Tilki M, Yegen C, Coskun S, Coskun M, Erdim A, Tanrikulu E, Yardimci S, Gunal O. Simultaneous resection for colorectal cancer with synchronous liver metastases is a safe procedure: Outcomes at a single center in Turkey. *Biosci Trends* 2017; **11**: 235-242 [PMID: 28216517 DOI: 10.5582/bst.2017.01019]

20 **Viganò L**, Russolillo N, Ferrero A, De Rosa G, Ferreri E, Forchino F, Sperti E, Capussotti L. Resection of liver metastases from colorectal mucinous adenocarcinoma: is this a different disease? Results of a case-control study. *Ann Surg* 2014; **260**: 878-884; discussion 884-885 [PMID: 25379857 DOI: 10.1097/SLA.0000000000000981]

21 **Russolillo N**, Sperti E, Langella S, Menonna F, Allieta A, Di Maio M, Ferrero A. Impact of primary tumor location on patterns of recurrence and survival of patients undergoing resection of liver metastases from colon cancer. *HPB (Oxford)* 2020; **22**: 116-123 [PMID: 31235431 DOI: 10.1016/j.hpb.2019.05.014]

22 **Heise D**, Bayings W, Tuinhof A, Eickhoff R, Kroh A, Ulmer F, Dejong CHC, Neumann U, Binnebösel M. Long-term outcome and quality of life after initial and repeat resection of colorectal liver metastasis: A retrospective analysis. *Int J Surg* 2017; **48**: 281-285 [PMID: 29175019 DOI: 10.1016/j.ijsu.2017.11.032]

23 **Sasaki K**, Andreatos N, Margonis GA, He J, Weiss M, Johnston F, Wolfgang C, Antoniou E, Pikoulis E, Pawlik TM. The prognostic implications of primary colorectal tumor location on recurrence and overall survival in patients undergoing resection for colorectal liver metastasis. *J Surg Oncol* 2016; **114**: 803-809 [PMID: 27792291 DOI: 10.1002/jso.24425]

24 **de Haas RJ**, Wicherts DA, Salloum C, Andreani P, Sotirov D, Adam R, Castaing D, Azoulay D. Long-term outcomes after hepatic resection for colorectal metastases in young patients. *Cancer* 2010; **116**: 647-658 [PMID: 19998351 DOI: 10.1002/cncr.24721]

25 **Lionti S**, Reggiani Bonetti L, Bettelli S, Spallanzani A, Gelsomino F, Barresi V. Histopathological variables in liver metastases of patients with stage IV colorectal cancer: potential prognostic relevance of poorly differentiated clusters. *Hum Pathol* 2018; **78**: 115-124 [PMID: 29715463 DOI: 10.1016/j.humpath.2018.04.019]

26 **Yamashita S**, Brudvik KW, Kopetz SE, Maru D, Clarke CN, Passot G, Conrad C, Chun YS, Aloia TA, Vauthey JN. Embryonic Origin of Primary Colon Cancer Predicts Pathologic Response and Survival in Patients Undergoing Resection for Colon Cancer Liver Metastases. *Ann Surg* 2018; **267**: 514-520 [PMID: 28002060 DOI: 10.1097/SLA.0000000000002087]

27 **Zhou F**, Yu X, Liang P, Han Z, Cheng Z, Yu J, Liu F, Hu Y. Does primary tumor location impact the prognosis of colorectal liver metastases patients after microwave ablation? - Lessons from 10 years' experience. *Oncotarget* 2017; **8**: 100791-100800 [PMID: 29246023 DOI: 10.18632/oncotarget.18764]

28 **Gu Y**, Huang Z, Gu H, Gao F, Zhang T, Huang S, Huang J. Does the Site of the Primary Affect Outcomes When Ablating Colorectal Liver Metastases with Radiofrequency Ablation? *Cardiovasc Intervent Radiol* 2018; **41**: 912-919 [PMID: 29582125 DOI: 10.1007/s00270-018-1937-9]

29 **Chafai N**, Chan CL, Bokey EL, Dent OF, Sinclair G, Chapuis PH. What factors influence survival in patients with unresected synchronous liver metastases after resection of colorectal cancer? *Colorectal Dis* 2005; **7**: 176-181 [PMID: 15720359 DOI: 10.1111/j.1463-1318.2004.00744.x]

30 **Zhang RX**, Ma WJ, Gu YT, Zhang TQ, Huang ZM, Lu ZH, Gu YK. Primary tumor location as a predictor of the benefit of palliative resection for colorectal cancer with unresectable metastasis. *World J Surg Oncol* 2017; **15**: 138 [PMID: 28750680 DOI: 10.1186/s12957-017-1198-0]

31 **Zheng P**, Ren L, Feng Q, Zhu D, Chang W, He G, Ji M, Jian M, Lin Q, Yi T, Wei Y, Xu J. Patients with RAS wild-type right-sided unresectable liver-confined mCRC also benefit from cetuximab plus chemotherapy in first-line treatment. *Am J Cancer Res* 2018; **8**: 2337-2345 [PMID: 30555748]

32 **Amikura K**, Akagi K, Ogura T, Takahashi A, Sakamoto H. The RAS mutation status predicts survival in patients undergoing hepatic resection for colorectal liver metastases: The results from a genetic analysis of all-RAS. *J Surg Oncol* 2018; **117**: 745-755 [PMID: 29194647 DOI: 10.1002/jso.24910]

33 **Schirripa M**, Bergamo F, Cremolini C, Casagrande M, Lonardi S, Aprile G, Yang D, Marmorino F, Pasquini G, Sensi E, Lupi C, De Maglio G, Borrelli N, Pizzolitto S, Fasola G, Bertorelle R, Rugge M, Fontanini G, Zagonel V, Loupakis F, Falcone A. BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection. *Br J Cancer* 2015; **112**: 1921-1928 [PMID: 25942399 DOI: 10.1038/bjc.2015.142]

34 **Umeda Y**, Nagasaka T, Mori Y, Sadamori H, Sun DS, Shinoura S, Yoshida R, Satoh D, Nobuoka D, Utsumi M, Yoshida K, Yagi T, Fujiwara T. Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability. *J Hepatobiliary Pancreat Sci* 2013; **20**: 223-233 [PMID: 23010994 DOI: 10.1007/s00534-012-0531-9]

35 **Imai K**, Yamashita YI, Miyamoto Y, Nakao Y, Yusa T, Itoyama R, Nakagawa S, Okabe H, Hiyoshi Y, Nitta H, Chikamoto A, Baba H. Implication of primary tumor location for the indication of preoperative chemotherapy in patients with colorectal liver metastases. *HPB (Oxford)* 2019; **21**: 405-412 [PMID: 30266494 DOI: 10.1016/j.hpb.2018.08.012]

36 **Koch C**, Schmidt N, Winkelmann R, Eichler K, Pession U, Bechstein WO, Zeuzem S, Waidmann O, Trojan J. Anti-EGF Receptor-Based Conversion Chemotherapy in RAS Wild-Type Colorectal Cancer Patients: Impact on Survival and Resection Rates. *Digestion* 2018; **98**: 263-269 [PMID: 30130797 DOI: 10.1159/000490888]

37 **Makowiec F**, Menzel M, Bronsert P, Holzner PA, Klock A, Lang SA, Fichtner-Feigl S, Neeff HP. Does the site of primary colorectal cancer influence the outcome after resection of isolated liver metastases? *Dig Liver Dis* 2018; **50**: 1088-1092 [PMID: 30055964 DOI: 10.1016/j.dld.2018.06.019]

38 **Wang K**, Xu D, Yan XL, Poston G, Xing BC. The impact of primary tumour location in patients undergoing hepatic resection for colorectal liver metastasis. *Eur J Surg Oncol* 2018; **44**: 771-777 [PMID: 29580735 DOI: 10.1016/j.ejso.2018.02.210]

39 **Mavros MN**, Hyder O, Pulitano C, Aldrighetti L, Pawlik TM. Survival of patients operated for colorectal liver metastases and concomitant extra-hepatic disease: external validation of a prognostic model. *J Surg Oncol* 2013; **107**: 481-485 [PMID: 22952157 DOI: 10.1002/jso.23260]

40 **Connor AA**, McNamara K, Al-Sukhni E, Diskin J, Chan D, Ash C, Lowes LE, Allan AL, Zogopoulos G, Moulton CA, Gallinger S. Central, But Not Peripheral, Circulating Tumor Cells are Prognostic in Patients Undergoing Resection of Colorectal Cancer Liver Metastases. *Ann Surg Oncol* 2016; **23**: 2168-2175 [PMID: 26714949 DOI: 10.1245/s10434-015-5038-6]

41 **Eefsen RL**, Vermeulen PB, Christensen IJ, Laerum OD, Mogensen MB, Rolff HC, Van den Eynden GG, Høyer-Hansen G, Osterlind K, Vainer B, Illemann M. Growth pattern of colorectal liver metastasis as a marker of recurrence risk. *Clin Exp Metastasis* 2015; **32**: 369-381 [PMID: 25822899 DOI: 10.1007/s10585-015-9715-4]

42 **Loosen SH**, Heise D, Dejong CH, Roy S, Tacke F, Trautwein C, Roderburg C, Luedde T, Neumann UP, Binnebösel M. Circulating Levels of Osteopontin Predict Patients' Outcome after Resection of Colorectal Liver Metastases. *J Clin Med* 2018; **7**: 390 [PMID: 30373147 DOI: 10.3390/jcm7110390]

43 **Palkovics A**, Vereczkei A, Kalmár KN, Fincsur A, Kiss I, Németh B, Papp A. The Issue of Survival After Colorectal Liver Metastasis Surgery: Parenchyma Sparing *vs*. Radicality. *Anticancer Res* 2018; **38**: 6431-6438 [PMID: 30396968 DOI: 10.21873/anticanres.13004]

44 **Shigematsu Y**, Inamura K, Yamamoto N, Mise Y, Saiura A, Ishikawa Y, Takahashi S, Kanda H. Impact of CDX2 expression status on the survival of patients after curative resection for colorectal cancer liver metastasis. *BMC Cancer* 2018; **18**: 980 [PMID: 30326864 DOI: 10.1186/s12885-018-4902-8]

45 **Rhu J**, Heo JS, Choi SH, Choi DW, Kim JM, Joh JW, Kwon CHD. Streamline flow of the portal vein affects the lobar distribution of colorectal liver metastases and has a clinical impact on survival. *Ann Surg Treat Res* 2017; **92**: 348-354 [PMID: 28480180 DOI: 10.4174/astr.2017.92.5.348]

46 **Wang Y**, Yuan YF, Lin HC, Li BK, Wang FH, Wang ZQ, Ding PR, Chen G, Wu XJ, Lu ZH, Pan ZZ, Wan DS, Sun P, Yan SM, Xu RH, Li YH. Pathologic response after preoperative therapy predicts prognosis of Chinese colorectal cancer patients with liver metastases. *Chin J Cancer* 2017; **36**: 78 [PMID: 28969708 DOI: 10.1186/s40880-017-0244-1]

47 **Berardi G**, De Man M, Laurent S, Smeets P, Tomassini F, Ariotti R, Hoorens A, van Dorpe J, Varin O, Geboes K, Troisi RI. Radiologic and pathologic response to neoadjuvant chemotherapy predicts survival in patients undergoing the liver-first approach for synchronous colorectal liver metastases. *Eur J Surg Oncol* 2018; **44**: 1069-1077 [PMID: 29615295 DOI: 10.1016/j.ejso.2018.03.008]

48 **Elizabeth McCracken EK**, Samsa GP, Fisher DA, Farrow NE, Landa K, Shah KN, Blazer DG 3rd, Zani S. Prognostic significance of primary tumor sidedness in patients undergoing liver resection for metastatic colorectal cancer. *HPB (Oxford)* 2019; **21**: 1667-1675 [PMID: 31155452 DOI: 10.1016/j.hpb.2019.03.365]

49 **McVey JC**, Sasaki K, Margonis GA, Nowacki AS, Firl DJ, He J, Berber E, Wolfgang C, Miller CC, Weiss M, Aucejo FN. The impact of resection margin on overall survival for patients with colon cancer liver metastasis varied according to the primary cancer location. *HPB (Oxford)* 2019; **21**: 702-710 [PMID: 30501989 DOI: 10.1016/j.hpb.2018.11.001]

50 **Adam R**, de Haas RJ, Wicherts DA, Vibert E, Salloum C, Azoulay D, Castaing D. Concomitant extrahepatic disease in patients with colorectal liver metastases: when is there a place for surgery? *Ann Surg* 2011; **253**: 349-359 [PMID: 21178761 DOI: 10.1097/SLA.0b013e318207bf2c]

51 **Suthananthan AE,** Bhandari M, Platell C. Influence of primary site on metastatic distribution and survival in stage IV colorectal cancer. *ANZ J Surg* 2018; **88**: 445–449 [PMID: 28512795 DOI: 10.1111/ans.13969]

52 **Margonis GA**, Buettner S, Andreatos N, Kim Y, Wagner D, Sasaki K, Beer A, Schwarz C, Løes IM, Smolle M, Kamphues C, He J, Pawlik TM, Kaczirek K, Poultsides G, Lønning PE, Cameron JL, Burkhart RA, Gerger A, Aucejo FN, Kreis ME, Wolfgang CL, Weiss MJ. Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer. *JAMA Surg* 2018; **153**: e180996 [PMID: 29799910 DOI: 10.1001/jamasurg.2018.0996]

53 **Sasaki K**, Margonis GA, Wilson A, Kim Y, Buettner S, Andreatos N, Gani F, Amini N, Spolverato G, Pawlik TM. Prognostic Implication of KRAS Status after Hepatectomy for Colorectal Liver Metastases Varies According to Primary Colorectal Tumor Location. *Ann Surg Oncol* 2016; **23**: 3736-3743 [PMID: 27352204 DOI: 10.1245/s10434-016-5361-6]

54 **Shindoh J**, Nishioka Y, Yoshioka R, Sugawara T, Sakamoto Y, Hasegawa K, Hashimoto M, Kokudo N. KRAS Mutation Status Predicts Site-Specific Recurrence and Survival After Resection of Colorectal Liver Metastases Irrespective of Location of the Primary Lesion. *Ann Surg Oncol* 2016; **23**: 1890-1896 [PMID: 26786089 DOI: 10.1245/s10434-016-5087-5]

55 **Brudvik KW**, Kopetz SE, Li L, Conrad C, Aloia TA, Vauthey JN. Meta-analysis of KRAS mutations and survival after resection of colorectal liver metastases. *Br J Surg* 2015; **102**: 1175-1183 [PMID: 26206254 DOI: 10.1002/bjs.9870]

56 **Goffredo P**, Utria AF, Beck AC, Chun YS, Howe JR, Weigel RJ, Vauthey JN, Hassan I. The Prognostic Impact of KRAS Mutation in Patients Having Curative Resection of Synchronous Colorectal Liver Metastases. *J Gastrointest Surg* 2019; **23**: 1957-1963 [PMID: 30276588 DOI: 10.1007/s11605-018-3978-4]

57 **Huang CJ**, Teng HW, Chien CC, Lin JK, Yang SH. Prognostic significance of C-reactive protein polymorphism and KRAS/BRAF in synchronous liver metastasis from colorectal cancer. *PLoS One* 2014; **8**: e65117 [PMID: 23755178 DOI: 10.1371/journal.pone.0065117]

58 **Iacopetta B**. Are there two sides to colorectal cancer? *Int J Cancer* 2002; **101**: 403-408 [PMID: 12216066 DOI: 10.1002/ijc.10635]

59 **Kawakami H**, Zaanan A, Sinicrope FA. Microsatellite instability testing and its role in the management of colorectal cancer. *Curr Treat Options Oncol* 2015; **16**: 30 [PMID: 26031544 DOI: 10.1007/s11864-015-0348-2]

60 **Taieb J**, Shi Q, Pederson L, Alberts S, Wolmark N, Van Cutsem E, de Gramont A, Kerr R, Grothey A, Lonardi S, Yoshino T, Yothers G, Sinicrope FA, Zaanan A, André T. Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies. *Ann Oncol* 2019; **30**: 1466-1471 [PMID: 31268130 DOI: 10.1093/annonc/mdz208]

61 **Jernvall P**, Mäkinen MJ, Karttunen TJ, Mäkelä J, Vihko P. Microsatellite instability: impact on cancer progression in proximal and distal colorectal cancers. *Eur J Cancer* 1999; **35**: 197-201 [PMID: 10448259 DOI: 10.1016/S0959-8049(98)00306-2]

62 **Cancer Genome Atlas Network.** Comprehensive molecular characterization of human colon and rectal cancer. *Nature* 2012; **487**: 330-337 [PMID: 22810696 DOI: 10.1038/nature11252]

63 **Banias L**, Gurzu S, Kovacs Z, Bara T, Bara T Jr, Jung I. Nuclear maspin expression: A biomarker for budding assessment in colorectal cancer specimens. *Pathol Res Pract* 2017; **213**: 1227-1230 [PMID: 28780084 DOI: 10.1016/j.prp.2017.07.025]

64 **You XH**, Jiang YH, Fang Z, Sun F, Li Y, Wang W, Xia ZJ, Wang XZ, Ying HQ. Chemotherapy plus bevacizumab as an optimal first-line therapeutic treatment for patients with right-sided metastatic colon cancer: a meta-analysis of first-line clinical trials. *ESMO Open* 2020; **4**: e000605 [PMID: 32132090 DOI: 10.1136/esmoopen-2019-000605]

**Footnotes**

**Conflict-of-interest statement:** The authors declare no conflicts of interest.

**PRISMA 2009 Checklist statement:** The authors have read the PRISMA 2009 Checklist and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited Manuscript

**Peer-review started:** December 31, 2019

**First decision:** March 15, 2020

**Article in press:** May 14, 2020

**Specialty type:** Oncology

**Country/Territory of origin:** United Kingdom

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B, B

Grade C (Good): C, C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Gurzu S, Kucherlapati MH, Osawa S, SunXT **S-Editor:** Wang J **L-Editor:** A **E-Editor:** Liu MY

**Figure Legends**

Publications identified through searching MEDLINE, EMBASE and COCHRANE (*n* = 4094)

Studies excluded after screening titles and abstracts (*n* = 3700)

Inappropriate article type (*n* = 2104)

Lack of required data (*n* = 1207)

Duplication of search results or data (*n* = 389)

Number of full articles retrieved and assessed for eligibility (*n* = 394)

Articles chosen for full text review (*n* = 420)

)

Articles included in review   
(*n* = 41)

Articles from reference searches  
(*n* = 26)

Full text articles excluded (*n* = 379)

Lack of liver metastasis specific outcome data (*n* = 324)

Unable to access full article in English (*n* = 36)

Duplication of data sets (*n* = 19)

**Figure 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses diagram summarising study selection process.**

**Table 1 Summary of characteristics of included studies**

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Ref. | Year | Country of study | Number of patients included | Median follow up (mo) | Primary tumour location (*n*) | | | Median age (yr) | | |
| **L** | **R** | **Rectum** | **L** | **R** | **Rectum** |
| Zhou *et al*[27] | 2017 | China | 295 | 24 | 89 | 94 | 112 | 57 | 59 | 61 |
| Zhang *et al*[30] | 2017 | China | 194 | 12 | 144 | 50 |  | 60 | 55.5 |  |
| Makowiec *et al*[37] | 2018 | Germany | 221 |  | 158 | 63 |  | 64 | 65 |  |
| Chafai *et al*[29] | 2005 | Australia | 398 | 26.8 | 277 | 71 |  |  |  |  |
| Rougier *et al*[15] | 1995 | France | 537 |  | 197 | 117 | 223 |  |  |  |
| Wang *et al*[38] | 2018 | China | 420 | 26 | 334 | 86 |  | 57 | 58.5 |  |
| Gu *et al*[28] | 2018 | China | 102 |  | 51 | 51 |  | 63 | 61.5 |  |
| Gasser *et al*[12] | 2019 | Austria | 259 | 38.1 | 200 | 59 |  | 64 | 66 |  |
| de Haas *et al*[24] | 2010 | France | 750 | 39 | 413 | 154 | 200 |  |  |  |
| Marques *et al*[11] | 2018 | Brazil | 151 | 42 | 124 | 27 |  | 57 | 61 |  |
| Russolillo *et al*[21] | 2019 | Italy | 686 | 81 | 364 | 322 |  | 63 | 66 |  |
| Umeda *et al*[34] | 2013 | Japan | 100 | 36 | 40 | 23 | 37 |  |  |  |
| Zheng *et al*[31] | 2018 | China | 318 |  | 233 | 85 |  |  |  |  |
| Mavros *et al*[39] | 2013 | United States | 97 | 26.4 | 44 | 24 | 27 |  |  |  |
| Viganò *et al*[20] | 2014 | Italy | 749 | 51.4 | 63 | 87 | 48 |  |  |  |
| Connor *et al*[40] | 2016 | Canada | 63 | 31.5 | 27 | 10 | 21 |  |  |  |
| Eefsen *et al*[41] | 2015 | Denmark | 254 | 44.6 | 125 | 51 | 78 |  |  |  |
| Schirripa *et al*[33] | 2015 | Italy | 309 | 45.6 | 138 | 87 | 82 |  |  |  |
| Loosen *et al*[42] | 2018 | Germany | 125 |  | 102 | 23 |  |  |  |  |
| Amikura *et al*[32] | 2018 | Japan | 342 | 52.7 | 236 | 106 |  |  |  |  |
| Yamashita *et al*[26] | 2018 | United States | 725 | 27/41 | 487 | 238 |  | 56 | 58 |  |
| Dulundu *et al*[19] | 2017 | Turkey | 108 |  | 40 | 24 | 44 | 58.5 | 63.2 | 63.8 |
| Creasy *et al*[9] | 2016 | United States | 907 | 132 | 578 | 329 |  | 62.4 | 65.4 |  |
| Sasaki *et al*[23] | 2016 | United States | 426 | 28.9 | 297 | 129 |  |  |  |  |
| Palkovics *et al*[43] | 2018 | Hungary | 319 |  | 114 | 72 | 133 |  |  |  |
| Dupré *et al*[8] | 2018 | United Kingdom | 364 | 41.8 | 290 | 74 |  | 65.1 | 68.6 |  |
| Heise *et al*[22] | 2017 | Germany | 160 | 21 | 113 | 47 |  |  |  |  |
| Shigematsu *et al*[44] | 2018 | Japan | 396 | 36.4 | 155 | 93 | 148 |  |  |  |
| Rhu *et al*[45] | 2017 | South Korea | 410 | 30.5 | 289 | 121 |  | 58.41 | 59.56 |  |
| Lionti *et al*[25] | 2018 | Italy | 63 | 40 | 22 | 23 | 18 |  |  |  |
| Wang *et al*[46] | 2017 | China | 159 |  | 130 | 29 |  |  |  |  |
| Norén *et al*[18] | 2015 | Sweden | 3125 |  | 1109 | 1092 | 924 |  |  |  |
| Berardi *et al*[47] | 2018 | Belgium | 62 | * 24 | 11 | 4 | 47 |  |  |  |
| Cremolini *et al*[16] | 2018 | Italy | 159 | 42.1 | 40 | 64 | 52 |  |  |  |
| McCracken *et al*[48] | 2019 | United States | 612 |  | 388 | 226 |  | 55 | 62 |  |
| McVey *et al*[49] | 2019 | United States | 732 | 26.8 | 397 | 336 |  | 59 | 62 |  |
| Imai *et al*[35] | 2019 | Japan | 163 | 38.8 | 127 | 36 |  |  |  |  |
| Koch *et al*[36] | 2018 | Germany | 30 |  | 24 | 5 | 1 |  |  |  |
| Liao *et al*[10] | 2018 | Taiwan | 1442 | 58. | 888 | 554 |  | 62.4 | 64.6 |  |
| Adam *et al*[50] | 2011 | France | 186 | 37 | 106 | 35 | 41 |  |  |  |
| Wang *et al*[17] | 2019 | China | 1508 |  | 557 | 593 | 358 |  |  |  |

De Haas *et al*[24]: Transverse colon grouped with left rather than right sided primaries; Yamashita *et al*[26]: Data for study and validation sets respectively, midgut *vs* hindgut not left *vs* right. L: Left; R: Right.

**Table 2 Overall survival data**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Year** | **Median OS (mo)** | | | | **5 Year OS (%)** | | | | **OS Hazard ratio** | | | |
| **L** | **R** | **Rectum** | ***P* value** | **L** | **R** | **Rectum** | ***P* value** | **L** | **R** | **Rectum** | ***P* value** |
| Zhou *et al*[27] | 2017 | 35 | 33 | 32 |  | 27.5 | 23.1 | 23 |  | 0.85 | 1 | 1.02 |  |
| Zhang*et al*[30] | 2017 | 22 | 12 |  | 0.012a |  |  |  |  |  |  |  |  |
| 14 | 10 |  |  |  |  |  |  |  |  |  |  |
| Makowiec *et al*[37] | 2018 |  |  |  |  | 41 | 46 |  |  |  |  |  |  |
| Chafai *et al*[29] | 2005 |  |  |  |  | 22.5 | 9.9 |  | < 0.001a | 1 | 1.68 |  | < 0.001a |
| Rougier *et al*[15] | 1995 | 8.2 | 4.5 | 7.6 | < 0.001a |  |  |  |  |  |  |  |  |
| 6.8 | 3.8 | 6.6 | < 0.001a |  |  |  |  |  |  |  |  |
| Wang *et al*[38] | 2018 |  |  |  |  | 38.3 | 46.5 |  |  | 1 | 1.08 |  |  |
| Gu *et al*[28] | 2018 | 40.3 | 29.4 |  | 0.042a |  |  |  |  | 1 | 6.2 |  | < 0.001a |
| Gasser *et al*[12] | 2019 | 55.5 | 33.5 | 58.2 |  |  |  |  |  | 1 | 1.53 |  | 0.029a |
| de Haas *et al*[24] | 2010 |  |  |  |  | 54 | 36 | 48 | 0.001a | 1 | 1.5 |  |  |
| Marques *et al*[11] | 2018 |  |  |  |  |  |  |  |  | 1 | 2.1 |  |  |
| Russolillo *et al*[21] | 2019 | 63.3 | 35.7 |  | 0.002a |  |  |  |  | 0.82 | 1 |  | < 0.001a |
| Umeda *et al*[34] | 2013 |  |  |  |  |  |  |  |  | 1.24 | 1 | 1.62 |  |
| Zheng *et al*[31] | 2018 | 29.5 | 21.9 |  | < 0.001a |  |  |  |  | 0.5 | 1 |  | < 0.001a |
| Mavros *et al*[39] | 2013 |  |  |  |  |  |  |  |  | 1 | 1.09 |  |  |
| Viganò *et al*[20] | 2014 | 41.3 | 58.3 | 47.4 |  | 43.1 | 44.7 | 41.3 |  |  |  |  |  |
| Connor *et al*[40] | 2016 |  |  |  |  |  |  |  |  | 1 | 2.4 |  | 0.0321a |
| Eefsen *et al*[41] | 2015 |  |  |  |  |  |  |  |  | 0.63 | 1 | 0.57 | 0.045a |
| Schirripa *et al*[33] | 2015 | 57.3 | 35.5 | 61.1 | 0.017a |  |  |  |  | 1 | 1.59 | 0.95 | 0.017a |
| Loosen *et al*[42] | 2018 |  |  |  |  |  |  |  |  | 1 | 2.32 |  |  |
| Amikura *et al*[32] | 2018 |  |  |  |  | 56.1 | 48.4 |  |  | 1 | 1.287 |  |  |
| Yamashita *et al*[26] | 2018 |  |  |  |  | 52 | 32 |  | < 0.0001a | 1 | 2.04 |  | < 0.0001a |
|  |  |  |  | 78 | 55 |  | 0.003a | 1 | 1.9 |  | 0.0009a |
| Dulundu *et al*[19] | 2017 | 30.43 | 46.38 | 40.86 |  | 52.5 | 54.1 | 59 |  |  |  |  |  |
| Creasy *et al*[9] | 2016 | 62.4 | 43.2 |  |  | 50.4 | 38.5 |  | 0.028a | 1 | 1.22 |  | 0.028a |
| Sasaki *et al*[23] | 2016 | 55.3 | 44.1 |  | 0.033a | 53.7 | 41.5 |  |  | 0.76 | 1 |  | 0.033a |
| Palkovics *et al*[43] | 2018 | 39 | 36 | 40 |  |  |  |  |  |  |  |  |  |
| Dupré *et al*[8] | 2018 | 45.3 | 34.6 |  | 0.035a | 37.5 | 25.4 |  | 0.010a | 1 | 1.429 |  | 0.036a |
| Shigematsu *et al*[44] | 2018 |  |  |  |  |  |  |  |  | 0.67 | 1 | 0.63 |  |
| Rhu *et al*[45] | 2017 |  |  |  |  |  |  |  |  | 0.862 | 1 |  |  |
| Wang *et al*[46] | 2017 |  |  |  |  |  |  |  |  | 0.75 | 1 |  |  |
| Norén *et al*[18] | 2015 | 61 | 57 | 48 | 0.02a | 45.8 | 44.5 | 42.6 | 0.02a | 0.75 | 1 | 0.73 | < 0.001a |
| Cremolini *et al*[16] | 2018 |  |  |  |  |  |  |  |  | 0.96 | 1 |  |  |
| McCracken *et al*[48] | 2019 | 75.6 | 54 |  | < 0.001a |  |  |  |  | 1 | 1.6 |  | 0.001a |
| McVey *et al*[49] | 2019 | 43 | 44.2 |  |  |  |  |  |  | 1.108 | 1 |  |  |
| 79.4 | 64.6 |  | 0.037a |  |  |  |  | 0.629 | 0.788 |  | 0.024a |
| Imai *et al*[35] | 2019 |  |  |  |  | 55.5 | 52.3 |  |  | 1 | 3.44 |  | 0.021a |
| Koch *et al*[36] | 2018 |  |  |  |  |  |  |  |  | 0.66 | 1 |  |  |
| Liao *et al*[10] | 2018 |  |  |  |  | 75.2 | 61.7 |  | 0.005a |  |  |  |  |
| Adam *et al*[50] | 2011 |  |  |  |  | 31 | 0 | 36 | 0.003a | 1 | 2.2 |  | 0.003a |
| Wang *et al*[17] | 2019 |  |  |  |  | 40.1 | 24.6 |  | < 0.001a | 1 | 1.75 |  | < 0.001a |

Zhang *et al*[30]: Top group: Overall population, bottom row: Patients who did not receive chemotherapy; Rougier *et al*[15]: Resection subgroup data presented in row above non-resection subgroup data; Yamashita *et al*[26]: Data for study set displayed above data for validation set; McVey *et al*[49]: R1 Resection data displayed over R0 Resection data. OS: Overall Survival. a*P <* 0.05. L: Left; R: Right.

**Table 3 Disease free survival data**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Year** | **Median DFS (mo)** | | | | **3 yr DFS (%)** | | | | **DFS HR** | | | | |
| **L** | **R** | **Rectum** | ***P* value** | **L** | **R** | **Rectum** | ***P* value** | | **L** | **R** | **Rectum** | ***P* value** |
| Wang *et al*[38] | 2018 |  |  |  |  | 22.4 | 29.1 |  |  | |  |  |  |  |
| Gasser *et al*[12] | 2019 | 12.6 | 9.1 | 9.6 |  |  |  |  |  | |  |  |  |  |
| Marques *et al*[11] | 2018 |  |  |  |  |  |  |  |  | | 1 | 1.1 |  |  |
| Russolillo *et al*[21] | 2019 | 32.7 | 20.8 |  | 0.002a |  |  |  |  | |  |  |  |  |
| Connor *et al*[40] |  |  |  |  |  |  |  |  |  | | 1 | 1.6 |  |  |
| Eefsen *et al*[41] |  |  |  |  |  |  |  |  |  | | 0.60 | 1 | 0.92 |  |
| Schirripa *et al*[33] | 2015 |  |  |  |  | 12.0 | 10.7 | 12.6 |  | | 1 | 1.23 | 1.04 |  |
| Amikura *et al*[32] | 2018 |  |  |  |  | 35.4 | 32.3 |  |  | | 1.09 | 1 |  |  |
| Yamashita *et al*[26] | 2018 |  |  |  |  | 27 | 15 |  | 0.001a | | 1 | 1.71 |  | < 0.0001a |
|  |  |  |  | 41 | 21 |  | 0.001a | | 1 | 1.48 |  | < 0.0001a |
| Creasy *et al*[9] | 2016 |  |  |  |  | 37 | 29 |  |  | |  | 1.14 |  |  |
| Sasaki *et al*[23] | 2016 |  |  |  |  | 20.2 | 28 |  | 0.001a | |  |  |  |  |
| Heise *et al*[22] | 2017 |  |  |  |  |  |  |  |  | | 0.19 | 1 |  | 0.001a |
| Shigematsu *et al*[44] | 2018 |  |  |  |  |  |  |  |  | | 0.85 | 1 | 0.97 |  |
| Wang *et al*[46] | 2017 |  |  |  |  |  |  |  |  | | 1.36 | 1 |  |  |
| Berardi *et al*[47] | 2018 |  |  |  |  |  |  |  |  | | 1.06 | 1 | 1.63 |  |
| Cremolini *et al*[16] | 2018 |  |  |  |  |  |  |  |  | | 0.81 | 1 |  |  |
| Imai *et al*[35] | 2019 | 22.9 | 21.3 |  |  |  |  |  |  | |  |  |  |  |
| Liao *et al*[10] | 2018 |  |  |  |  | 70.9 | 66.5 |  | 0.033a | |  |  |  |  |

Yamashita *et al*[26]: Data for study set above data for validation set, midgut *vs* hindgut, not left *vs* right; Imai *et al*[35]: 5 Year DFS% not 3-year disease free survival. a*P <* 0.05. DFS: Disease free survival; L: Left; R: Right; HR: Hazard ratio.

**Table 4 Progression free survival data**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Year** | **Median PFS (mo)** | | | | **5 yr PFS (%)** | | | | **PFS HR** | | | |
| **L** | **R** | **Rectum** | ***P* value** | **L** | **R** | **Rectum** | ***P* value** | **L** | **R** | **Rectum** | ***P* value** |
| Zhou *et al*[27] | 2017 |  |  |  |  | 12.5 | 7.1 | 11.5 | 0.012a | 0.67 | 1 | 0.85 | 0.012a |
| de Haas *et al*[24] | 2010 |  |  |  |  | 18 | 16 | 7 | 0.009a |  |  |  |  |
| Zheng *et al*[31] | 2018 | 9.2 | 7.3 |  | 0.002a |  |  |  |  | 0.75 | 1 |  | 0.002a |
| Lionti *et al*[25] | 2018 |  |  |  |  |  |  |  |  | 0.5 | 1 | 1 |  |
| Liao *et al*[10] | 2018 |  |  |  |  | 70.9 | 66.5 |  | 0.033a |  |  |  |  |

a*P <* 0.05. PFS: Progression free survival; L: Left; R: Right; HR: Hazard ratio.